![\"Three](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/10\/three-medics-1200x675.jpg\")
<\/p>\n<\/p>\n
Image source: Getty Images<\/p>\n
ASX 200\u00a0healthcare shares<\/a> are outperforming on Friday, with the S&P\/ASX 200 Health Care Index (ASX: XHJ) up 0.4% compared to the S&P\/ASX 200 Index (ASX: XJO), which is up 0.25%. <\/p>\n In new notes, top broker Morgans has revealed its verdict on the three biggest ASX 200 healthcare shares on the market today. <\/p>\n Let’s take a look. <\/p>\n The CSL share price is $179.85 on Friday, up 0.16% today and down 36% in the year to date. <\/p>\n Morgans has a buy rating on the market’s largest ASX 200 healthcare share.<\/p>\n However, it’s concerned by an update from CSL flagging lower expected earnings and a delay in the demerger of the Seqirus division. <\/p>\n Morgans said: <\/p>\n Despite the majority of the business “tracking to plan”, FY26 cc guidance had been downgraded (2-3% at revenue and NPATA mid-points), mainly reflecting continued declines in US influenza vaccination rates, although Chinese government cost containment affecting albumin demand was also flagged. <\/p>\n Although it remains challenging to know when US influenza vaccination rates will stabilise, we believe the risk of a permanently lower base is being over-priced, with Seqirus and Vifor marked down, with even Behring trading below peers and well under its long-term average, which we see as unjustified. <\/p>\n The broker lowered its FY26-28 net profit forecasts by up to 14.3%, and reduced its 12-month share price target from $293.83 to $249.51. <\/p>\n Sigma Healthcare Ltd (ASX: SIG<\/a>) <\/p>\n The Sigma Healthcare share price is $3.12, up 0.48% today and up 16% in the year to date. <\/p>\n Morgans has an accumulate rating on Sigma Healthcare shares. <\/p>\n Sigma Healthcare became the market’s second-biggest ASX 200 healthcare share after its merger with Chemist Warehouse. <\/p>\n Morgans said Sigma Healthcare management provided an upbeat outlook at the annual general meeting last week<\/a>. <\/p>\n SIG provided positive commentary at its recent AGM around continued domestic and international store expansion, solid like-for-like sales and reconfirmation of synergy benefits. <\/p>\n At this stage we remain comfortable with our FY26 forecasts, which show sales and EBIT growth of 11.4% and 23.6% respectively. <\/p>\n We forecast EBIT growth to continue (~18%) for FY27\/28. <\/p>\n The broker has a 12-month share price target of $3.39 on this ASX 200 healthcare share. <\/p>\n